[Cooperative effect of rhIL-2 and adriamycin-magnetic albumin microsphere targeting therapy on tumor].
OBJECTIVE
To observe the synergistic inhibitory effects of rhIL-2 and adriamycin magnetic albumin microsphere(ADM-MAM) targeting therapy on tumor and to explore their antitumor mechanism.


METHODS
The antitumor activity was observed using the tumor weight as index. The killer activity of natural killer (NK) cells and the lymphocyte transformation were examined by the LDH release assay and MTT colorimetry, respectively. The apoptosis of tumor cells and the expressions of p53,Fas and FasL were examined by flow cytometry. The expressions of IL-2 and IL-12 were determined by RT-PCR.


RESULTS
Compared with the control group, in ADM-MAM targeting therapy group and combination therapy (ADM-MAM and rhIL-2 therapy) group, tumor weight, killer activity of NK cells, and the lymphocyte transformation;were obviously decreased; while the expression of Fas, FasL, IL-2 and IL-12 were markedly increased.


CONCLUSIONS
ADM-MAM targeting therapy exerts anti-tumor effects with fewer side effects, which can be enhanced when combined with rhIL-2 therapy. Such synergistic anti-tumor effects may be realized by stimulating the proliferation of T cells and growth of NK cell to enhance cellular immunological function.
Dong
Lan-feng
LF
Experiment Animal Department,Hebei Medical University, Shijia zhuang 050017, China. Donglanfengcn@yahoo.com.cn
Song
Shu-xia
SX
Hou
Jie
J
Lu
Zhan-jun
ZJ
D000418:Albumins / Q000008:administration & dosage*; D000818:Animals; D017209:Apoptosis; D004317:Doxorubicin / Q000008:administration & dosage*; D007376:Interleukin-2 / Q000494:pharmacology*; D007694:Killer Cells, Natural / Q000276:immunology; D008213:Lymphocyte Activation; D008280:Magnetics; D051379:Mice; D008807:Mice, Inbred BALB C; D008863:Microspheres; D009374:Neoplasms, Experimental / Q000188:drug therapy* / Q000276:immunology / Q000473:pathology; D011994:Recombinant Proteins / Q000494:pharmacology; D016159:Tumor Suppressor Protein p53 / Q000032:analysis; D019014:fas Receptor / Q000032:analysis
D000418:Albumins; D007376:Interleukin-2; D011994:Recombinant Proteins; D016159:Tumor Suppressor Protein p53; D019014:fas Receptor; D004317:Doxorubicin